Atlas Trials

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Clinical trial NCT03947242 · UNKNOWN

Trial details

NCT number
NCT03947242
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
HER2 Positive Breast Cancer
Start date
2019-06-01
Primary completion
2020-06-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.